-- Dr. Peterson’s extensive experience includes clinical development, medical affairs, and regulatory leadership in support of innovative oncology product portfolios --
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer. Dr. Peterson is a veteran oncology drug development leader whose experience includes senior clinical development and operational roles at Genentech, Medivation, BeiGene and CytomX. She joins Exelixis as the company accelerates development of its product pipeline and builds on the success of its global cabozantinib oncology franchise.
“With an exciting product pipeline and a culture of focused execution in the discovery, development and commercialization of differentiated oncology products, Exelixis stands apart in our industry,” said Dr. Peterson. “I’m excited to join the company and lead its development organization as it advances a new wave of potentially transformative therapies for patients in need.”
Dr. Peterson received her M.D. from Thomas Jefferson University, completed a residency in internal medicine at Northwestern Memorial Hospital and undertook a hematology/oncology fellowship at the University of Chicago. She began her industry career at Genentech, where she oversaw the development of early-stage molecules targeting multiple major pathways in oncology, including Investigational New Drug submission and phase 1 workstreams for atezolizumab (TECENTRIQ®). After Genentech, Dr. Peterson joined Medivation, where she was part of the filing team for the initial FDA approval of enzalutamide (XTANDI®) in prostate cancer and led breast cancer development for both enzalutamide and talazoparib (TALZENNA®). At BeiGene, she was the company’s Chief Medical Officer, IO, a role in which she built the company’s global oncology development organization with oversight of all early-stage assets and solid tumor indications, including the checkpoint inhibitor tislelizumab. Most recently, Dr. Peterson was at CytomX, first as Executive Vice President and Chief Development Officer and then as President and Chief Operating Officer.
“It’s a pleasure to welcome Dr. Amy Peterson to Exelixis as the company’s next Chief Medical Officer. With nearly eighteen years of clinical development leadership experience at some of biopharma’s most notable oncology innovators, she is well suited to further accelerate our product development organization’s work as we strive to do even more for patients with cancer,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. “The Exelixis team also extends its deep gratitude to Dr. Vicki Goodman for her contributions to the company during her tenure, and we wish her well.”
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on Twitter, like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.
This press release contains forward-looking statements, including, without limitation, statements related to the potential for Exelixis to advance a new wave of potentially transformative therapies for patients in need and Exelixis’ scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: uncertainties inherent in the product development process and other factors affecting Exelixis and its development programs discussed under the caption “Risk Factors” in Exelixis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 1, 2023 and Annual Report on Form 10-K filed with the SEC on February 7, 2023, and in Exelixis’ future filings with the SEC. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.
Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.
Investors Contact: Susan Hubbard Executive Vice President, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 firstname.lastname@example.org
Media Contact: Hal Mackins For Exelixis, Inc. 415-994-0040 email@example.com
Source: Exelixis, Inc.